Grant of Awards to Directors

RNS Number : 6212T

IXICO plc

31 March 2016

 

IXICO plc

Grant of Awards to Directors

31 March 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, today announces that on 29 March 2016 the Remuneration Committee agreed to grant options to the Company's Executive Directors and employees under the rules of the Company's EMI Share Option Plan 2014 (the "Scheme") exercisable at the placing price of 30.5p in accordance with the intention set out in the circular dated 18 November 2015.

The award of options under the Scheme are over the ordinary shares in the Company and are  subject to various conditions. There are three tranches of options granted under the Scheme subject to different vesting criteria.

For each Executive Director, 50% of options under the first tranche ("Tranche 1") vest at the end of 12 months and 50% vest at the end of 24 months. Options under the second tranche ("Tranche 2") vest if there is a 20% increase in the share price within twelve months of the date of grant. Options under the third tranche ("Tranche 3") vest upon the achievement of strategic corporate goals in respect of commercialisation of the Company's products/services or a significant corporate development transaction within three years of the date of grant.

The total number of options being issued at this time is 1,778,274.

The following table sets out the details of the options that have been granted to the Executive Directors:

Name of Director	Grant 1	Grant 2	Grant 3	Total number of options granted	Total number of options held	Percentage of existing issued shares under option
Derek Hill	30,117	200,000	200,000	430,117	490,353	1.85%
Susan Lowther	25,098	180,000	180,000	385,098	435,294	1.65%
Total	55,215	380,000	380,000	815,215	925,647	3.50%

Enquiries:

IXICO plc	[phone]
Derek Hill, CEO
Susan Lowther, CFO
Peel Hunt LLP (Nominated Adviser and Broker)	[phone]
James Steel / Oliver Jackson
Daniel Stewart & Company (Joint Broker)	[phone]
Martin Lampshire / David Coffman
FTI Consulting Limited (Investor Relations)	[phone]
Simon Conway / Mo Noonan / Matthew Moss

Notes to Editors

About IXICO

IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions.  In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes.  In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.

The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health.

More information is available on www.ixico.com

-----------------------

 

END

 

 

RDSMMGFFRGZGVZM